Supplement

Supplementary Figure 1. CONSORT Flow diagram



Seventy-seven CU patients were assessed for eligibility, and 63 patients were randomized and allocated to the treatment groups (21 patients in the rupatadine 10 mg OD and 42 patients in the rupatadine 10 mg daily continuously group). Fourteen patients were excluded from the study, 14 patients were lost during the study period. Finally, 18 patients of the "OD arm" and 31 patients in the "daily arm" completed the study according to the protocol and were analyzed as per-protocol set. *Sham up-dosing (placebo 20 mg and rupatadine 10 mg OD). #One case was not in remission but remained in the rupatadine 10 mg daily arm.